Microbial Drug Resistance · 2016 · 60 citations · 7 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceAntimicrobial Resistance EpidemiologyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsAntimicrobial Susceptibility TestingCystic FibrosisMultidrug ResistanceAntibiotic Resistance In Respiratory PathogensAntibiotic Susceptibility TestingBacterial Multidrug ResistanceMinimum Inhibitory Concentration DeterminationMinimum Inhibitory Concentration TestingMultidrug-resistant Organism IsolationMultidrug-resistant PathogensOxacillin Resistance
Pseudomonas aeruginosa and Staphylococcus aureus are common pathogens in cystic fibrosis (CF) patients with increasing multidrug resistance (MDR). This study characterized antimicrobial susceptibility trends among organisms isolated from the respiratory tract of CF patients. Microbiological culture and sensitivity results for all CF patients were collected from January 2010 through December 2014. Minimum inhibitory concentrations were obtained using Phoenix® and Etest® methods. Clinical and Laboratory Standards Institute guidelines were used to remove duplicate isolates and develop antimicrobial susceptibility reports. MDR was defined as resistance to one agent in three or more antibiotic classes or oxacillin resistance in S. aureus. Overall, 542 bacterial isolates from 376 cultures were analyzed for trends. P. aeruginosa (41%), S. aureus (40%), and Stenotrophomonas maltophilia (8%) were the most commonly isolated organisms. Multidrug-resistant organism isolation increased from 39% to 49% (r = 0.76, p = 0.13), while representing 47.6% of all isolates. Multidrug-resistant P. aeruginosa incidence increased each year from 26% to 43% (r = 0.89, p = 0.046), while P. aeruginosa isolation decreased from 47% to 38% over the study period (r = −0.93, p = 0.02). MRSA accounted for 62.6% of all S. aureus isolated, while overall multidrug-resistant S. aureus incidence was 73.1% in all cultures. MDR among common pathogens in CF continues to increase. Empiric therapy for CF exacerbations should be targeted to previous antimicrobial susceptibility, and P. aeruginosa and S. aureus should be empirically covered.
7
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
D. Hubert, Hélène Réglier‐Poupet, Isabelle Sermet‐Gaudelus et al. · Journal of Cystic Fibrosis · 2013 · 127 citations · Full text
Lise Crémet, Nathalie Caroff, Cécile Giraudeau et al. · Journal of Antimicrobial Chemotherapy · 2013 · 26 citations · Full text